Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism

Stefano Palomba, Francesco Orio, Michele Morelli, Tiziana Russo, Massimilano Pellicano, Carmine Nappi, Pasquale Mastrantonio, Gaetano Lombardi, Annamaria Colao, Fulvio Zullo

Research output: Contribution to journalArticle

Abstract

This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3.75 mg/d for 28 d and then randomized into two groups to receive raloxifene hydrochloride at 60 mg/d (group A) or placebo (1 tablet/d; group B). Bone mineral density (BMD) and serum bone metabolism markers were evaluated at admission and after six treatment cycles. Posttreatment BMD differed significantly from baseline BMD in group B but not in group A. BMD was significantly higher in group A than in group B. In group A, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were unchanged vs. baseline. Differently, posttreatment concentrations of these bone turnover markers were significantly lower in group B compared with baseline and group A values. In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas.

Original languageEnglish
Pages (from-to)4476-4481
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume87
Issue number10
DOIs
Publication statusPublished - Oct 1 2002

Fingerprint

Leiomyoma
Metabolism
Gonadotropin-Releasing Hormone
Bone Density
Bone
Bone and Bones
Minerals
Placebos
Leuprolide
Bone Remodeling
Osteocalcin
Controlled Clinical Trials
Serum
Tablets
Alkaline Phosphatase
Raloxifene Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas : Effects on bone metabolism. / Palomba, Stefano; Orio, Francesco; Morelli, Michele; Russo, Tiziana; Pellicano, Massimilano; Nappi, Carmine; Mastrantonio, Pasquale; Lombardi, Gaetano; Colao, Annamaria; Zullo, Fulvio.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 10, 01.10.2002, p. 4476-4481.

Research output: Contribution to journalArticle

Palomba, S, Orio, F, Morelli, M, Russo, T, Pellicano, M, Nappi, C, Mastrantonio, P, Lombardi, G, Colao, A & Zullo, F 2002, 'Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism', Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4476-4481. https://doi.org/10.1210/jc.2002-020780
Palomba, Stefano ; Orio, Francesco ; Morelli, Michele ; Russo, Tiziana ; Pellicano, Massimilano ; Nappi, Carmine ; Mastrantonio, Pasquale ; Lombardi, Gaetano ; Colao, Annamaria ; Zullo, Fulvio. / Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas : Effects on bone metabolism. In: Journal of Clinical Endocrinology and Metabolism. 2002 ; Vol. 87, No. 10. pp. 4476-4481.
@article{d41304d88ae74eb5b628c6b28132e308,
title = "Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism",
abstract = "This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3.75 mg/d for 28 d and then randomized into two groups to receive raloxifene hydrochloride at 60 mg/d (group A) or placebo (1 tablet/d; group B). Bone mineral density (BMD) and serum bone metabolism markers were evaluated at admission and after six treatment cycles. Posttreatment BMD differed significantly from baseline BMD in group B but not in group A. BMD was significantly higher in group A than in group B. In group A, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were unchanged vs. baseline. Differently, posttreatment concentrations of these bone turnover markers were significantly lower in group B compared with baseline and group A values. In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas.",
author = "Stefano Palomba and Francesco Orio and Michele Morelli and Tiziana Russo and Massimilano Pellicano and Carmine Nappi and Pasquale Mastrantonio and Gaetano Lombardi and Annamaria Colao and Fulvio Zullo",
year = "2002",
month = "10",
day = "1",
doi = "10.1210/jc.2002-020780",
language = "English",
volume = "87",
pages = "4476--4481",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas

T2 - Effects on bone metabolism

AU - Palomba, Stefano

AU - Orio, Francesco

AU - Morelli, Michele

AU - Russo, Tiziana

AU - Pellicano, Massimilano

AU - Nappi, Carmine

AU - Mastrantonio, Pasquale

AU - Lombardi, Gaetano

AU - Colao, Annamaria

AU - Zullo, Fulvio

PY - 2002/10/1

Y1 - 2002/10/1

N2 - This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3.75 mg/d for 28 d and then randomized into two groups to receive raloxifene hydrochloride at 60 mg/d (group A) or placebo (1 tablet/d; group B). Bone mineral density (BMD) and serum bone metabolism markers were evaluated at admission and after six treatment cycles. Posttreatment BMD differed significantly from baseline BMD in group B but not in group A. BMD was significantly higher in group A than in group B. In group A, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were unchanged vs. baseline. Differently, posttreatment concentrations of these bone turnover markers were significantly lower in group B compared with baseline and group A values. In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas.

AB - This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3.75 mg/d for 28 d and then randomized into two groups to receive raloxifene hydrochloride at 60 mg/d (group A) or placebo (1 tablet/d; group B). Bone mineral density (BMD) and serum bone metabolism markers were evaluated at admission and after six treatment cycles. Posttreatment BMD differed significantly from baseline BMD in group B but not in group A. BMD was significantly higher in group A than in group B. In group A, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were unchanged vs. baseline. Differently, posttreatment concentrations of these bone turnover markers were significantly lower in group B compared with baseline and group A values. In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas.

UR - http://www.scopus.com/inward/record.url?scp=18644371458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644371458&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-020780

DO - 10.1210/jc.2002-020780

M3 - Article

C2 - 12364422

AN - SCOPUS:18644371458

VL - 87

SP - 4476

EP - 4481

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -